



Medicines & Healthcare products
Regulatory Agency



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

OFFICIAL SENSITIVE – COMMERCIAL

[REDACTED]
AstraZeneca
Silk Road Business Park
Charter Court
Macclesfield
SK10 2NA
United Kingdom

Date 04/08/2022

Case No: Insp GMP/GDP/IMP 17901/10117-0048

**SUBJECT: THE HUMAN MEDICINES REGULATIONS 2012 (as amended) (SI 2012/1916)
THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 (SI 2004/1031)
AUTHORISATION / REGISTRATION NO. MIA 17901, MIA(IMP) 17901, MS 17901, WDA(H) 17901**

Dear [REDACTED]

Thank you for the courtesy and co-operation shown during the inspection of your premises at AstraZeneca, Silk Road Business Park, Charter Court, Macclesfield, SK10 2NA, United Kingdom on 02/08/2022 and 03/08/2022.

During the inspection a number of failures to comply with the principles and guidelines of Good Manufacturing Practice and / or Good Distribution Practice were observed and these are listed in the Appendix to this letter.

Please reply within 28 days, giving your proposals for dealing with these matters, together with a timetable for their implementation. Please send your response electronically by e-mail to me at the email address below.

It would be appreciated if your response was in the following format:

1. Restate the deficiency number and the deficiency as written below.
2. State the proposed corrective action and the target date for completion of these action(s)
3. Include any comment that the company considers appropriate.
4. Please provide the response as a word document.

File Ref: Insp GMP/GDP/IMP 17901/10117-0048

Inspection Date: 02/08/2022


Company: AstraZeneca, Macclesfield

Page 2 of 4

Further guidance on responding to inspection deficiencies can be found at the following web link <https://www.gov.uk/guidance/guidance-on-responding-to-a-gmpgdp-post-inspection-letter>

Yours sincerely


GMDP Inspector

E-mail: 

**FAILURES TO COMPLY WITH THE GUIDE TO GOOD MANUFACTURING /
DISTRIBUTION PRACTICE**

1. **CRITICAL**

None

2. **MAJOR**

None

3. **OTHER**

3.1 Deviation [REDACTED] did not adequately consider whether additional batches impacted by the trend of high microbiological counts in [REDACTED] binder solution should be included in the on-going stability monitoring programme, whether revising scheduled timepoints for microbiological stability testing would be appropriate, or if additional microbiological testing of bulk held for extended periods in drums (for example when transported overseas for packing) would be appropriate to confirm the stability of the product was unaffected.

EU GMP

C6.33

3.2 **Controls to minimize the risks of mix-ups were deficient in that:**

3.2.1 No risk assessment had been performed to evaluate the practice of simultaneously conducting two labelling operations of starting materials in the same warehouse pod, and therefore it could not be demonstrated that all required controls were in place and there was no risk of mix-up or substitution.

3.2.2 Containers were not always appropriately labelled to indicate their status, for example three drums of waste [REDACTED] API located in the [REDACTED] materials transfer area and several pallets of empty tablet containers that were stacked outside the Warehouse area were labelled as if they contained product.

EU GMP

C5.9, C5.12

3.3 **Documentation controls were deficient as evidenced by:**

3.3.1 Records were not always completed contemporaneously, for example the Macclesfield Warehouse Delivery Unloading checklist had not been completed when the checks had been performed, and it was explained this would be completed later from memory.

3.3.2 Uncontrolled paper with information related to a production batch was observed adhered to a pallet of [REDACTED] (PO

Page 4 of 4

3.3.3	<div>██████████</div> <p>Documents were not always kept up to date, for example the Dispensary Area Logbook referred to a night shift that had not been in place for some time, and despite being identified as an issue during an internal audit, no CAPA had been raised to amend it or consider other documents that may similarly be affected.</p>
EU GMP	C4.5, C4.8, C4.10
3.4	Equipment and facility controls were deficient as evidenced by:
3.4.1	The binder preparation vessel appeared to have rivets missing causing gaps between the stainless steel panels that potentially made the equipment harder to keep clean.
3.4.2	Trolleys used for transporting compression equipment parts were noted to not to be kept in a state of good repair and presented a potential contamination risk to the facility.
3.4.3	The sink in the granulation suite was noted to be chipped exposing rough surfaces that were potentially difficult to keep clean.
3.4.4	There was no requirement to periodically change key press codes for doors leading into production areas therefore ensuring they were appropriately secure to prevent the entry of unauthorised people.
EU GMP	C3.5, C3.34, C3.36, C5.10
3.5	There was no risk-based justification to support the site's position of not requiring the reconciliation of serialized tamper evident seals that were applied to deliveries of starting materials.
EU GMP	C5.30

4. **COMMENT**

None